The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.
This report provides:
-An overview of the global market for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.
-Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
-Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.
-Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity.
-Comprehensive profiles of leading generics companies, and updates on mergers and acquisitions.
STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2018; these are based on industry sources and a considered assessment of the regulatory environment, healthcare policies, demographics and other factors that directly affect the generic drug market. The wider economic environment is also taken into account.Read » Global Markets for Generic Drugs